Nonfat Milk Supplementation Mitigates Hepatic Lipid Accumulation and Improves Hepatic Lipid Metabolism in an Early Metabolic Dysfunction-Associated Steatotic Liver Disease C57BL/6N Mouse Model.

ABSTRACT:

Background

Dairy products may mitigate metabolic dysfunction-associated steatotic liver disease (MASLD) progression, but the role of dairy fat is unclear.

Objectives

This animal trial compared MASLD-related outcomes after feeding nonfat milk (NFM) or whole-fat milk (WFM) in a high-fat diet (HFD)-induced MASLD mouse model.

Methods

Male C57BL/6N mice were fed a HFD (45% kcal fat; n = 40) for 9 wk. During the last 8 wk, 2 randomly selected groups additionally consumed 0.425 mL NFM (0 g% fat; n = 8) or WFM (3.25 g% fat; n = 12), from a small dish, 5 d/wk. A low-fat diet group (10% kcal fat; n = 20) served as a reference. The metabolic phenotype and liver lipid metabolism pathways were studied and compared by 1-way analysis of variance; P ≤ 0.05 was considered significant.

SUBMITTER: Berg E 

PROVIDER: S-EPMC12799403 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature